Palantir's stock is seeing a boost from reports that the U.S. and Saudi Arabian governments have reached a new deal that ...

Palantir Technologies smashed through a major milestone Tuesday, topping a $300 billion market cap for the first time ever ...

With its 3-star rating, we believe Palantir stock is fairly valued compared with our long-term fair value estimate of $100 per share, which implies a 2025 enterprise value/sales multiple of 57 times.

In the first quarter of 2025, Palantir reported revenues of $884 million, a 39% year-over-year increase. The U.S. commercial ...

However, one Wall Street analyst remains very bullish on the stock's prospects. Wedbush analyst Dan Ives reiterated an outperform (buy) rating on the shares and raised the firm's price target from ...

Palantir stock tumbled Tuesday as investors scrutinized the company's high valuation and declining sales to international ...

Palantir shares have advanced 550% since January 2024, which makes it the best performing stock in the S&P 500 and the second ...

Palantir stock has been on a tear in 2025, rising more than 40% even after Tuesday's big drop. Analysts have expressed ...

Palantir upped full-year guidance and delivered an above-consensus guide for Q2 FY 2025, thereby completing a triple play.

Palantir shares tumbled Tuesday despite the company's strong results and outlook, as investors may have expected more from ...

Five Wall Street banks have revised their Palantir stock price targets — and most see downside in the cards for the data ...

Another notable buy includes CRISPR Therapeutics AG (NASDAQ: CRSP ), with ARKK ETF purchasing 31,983 shares, reflecting a continued investment in the gene-editing company with a total dollar value of ...